This study is testing an experimental drug called CYH33 for women with a specific type of recurrent ovarian cancer (clear cell carcinoma) that has a particular genetic change (PIK3CA mutation). It is for patients whose cancer has come back or persisted after standard chemotherapy…
Phase: PHASE2 • Sponsor: Haihe Biopharma Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC